Abbott Laboratories (ABT)

Abbott Laboratories' stock price has recently declined, reaching multi-year lows. In November 2025, Abbott agreed to acquire Exact Sciences Corp, which is expected to increase sales but dilute earnings per share. Abbott received FDA approval for its Aveir DR leadless pacemaker system in July 2023 and clearance for its Ultreon 3.0 Software in May 2026. In Q1 2026, Abbott reported adjusted earnings per share that met expectations and revenue that beat estimates, although organic growth was weaker than expected due to issues in the diabetes and respiratory segments.

Demand for Abbott Laboratories' products can be seasonal, particularly for diagnostic products related to respiratory illnesses. A weaker respiratory season in Q1 2026 negatively impacted sales in the rapid and molecular diagnostics segment. While a general seasonality chart for ABT stock exists, past patterns do not guarantee future performance.

Abbott Laboratories is a multinational medical devices and healthcare company based in Abbott Park, Illinois. It operates in the healthcare sector, focusing on medical devices and pharmaceuticals. Abbott's business is divided into four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Key products include branded generic pharmaceuticals, diagnostic systems and tests, nutritional products for all life stages, and medical devices for various conditions. Recent acquisitions have expanded its presence in vascular care and smart insulin management systems.

Abbott Laboratories has a global presence, operating in over 160 countries. The United States accounts for the largest portion of its revenue. The Established Pharmaceuticals Division focuses on emerging markets outside the U.S. and Western Europe, with key markets in Latin America, Southeast Asia, the Middle East, and Africa.

Abbott's brand reputation has been affected by a major recall in 2022, which led to market share loss in the nutrition segment, and ongoing infant formula litigation. However, recent FDA clearance for its Ultreon 3.0 Software demonstrates Abbott's commitment to innovation in medical technology.

Abbott Laboratories is primarily owned by institutional shareholders, who hold approximately 80% to 82.08% of the company. Insiders own a smaller percentage, around 0.48% to 1.17%, while retail investors hold about 16.76% to 45.72% of the shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp.